TrialBlood neoplasia2025

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study.

Yu Uemura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.